Lumosa Therapeutics's newly appointed General Manager, Mr. Yeh Sheng-wen, stated during a press conference on the 14th that the enrollment speed for the clinical trials of LT3001 in Mainland China, which is being conducted by its partner Shanghai Pharmaceutical Group, has exceeded expectations. Currently, over 80% of the targeted participants have been enrolled. It is expected to complete patient enrollment (Last Patient In, LPI) by mid-year, with the unblinding schedule by year-end proceeding as planned.
Additionally, Lumosa Therapeutics is planning to complete two multinational clinical trials by 2025.
In order to expand its operational scope, Lumosa Therapeutics is actively investing resources in next-generation potential therapies. In addition to exosomes and allogeneic cell therapy, it has recently ventured into the field of gene therapy through an investment in the innovative gene editing technology company, GenEditBio. The company is exploring the possibilities of various emerging therapies. Lumosa Therapeutics's long-acting analgesic injection, LT1001, which has already been marketed, has obtained regulatory approval in six countries. It continues to expand its licensing efforts to penetrate niche markets to serve as a stable cash flow for the company's phased stability.
In addition to announcing the progress of new drugs, Lumosa Therapeutics also announced during the conference on the 14th that it will conduct a cash capital increase by issuing new shares and approve new personnel appointments. The largest shareholder, Shengde Group, has appointed Ms. Wang Suqi as the chairman, and Dr. Ye Shengwen, former head of the preclinical research department, as the general manager. The former chairman and general manager, Mr. Lin Rongjin, has temporarily resigned to undertake phased tasks.
Resource (Mandarin):
